News
NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback